Literature DB >> 7824274

scl, a gene frequently activated in human T cell leukaemia, does not induce lymphomas in transgenic mice.

L Robb1, J E Rasko, M L Bath, A Strasser, C G Begley.   

Abstract

The scl gene is implicated in human T cell acute lymphoblastic leukaemia (T-ALL) through its involvement in the t(1;14)(p32;q11) chromosomal translocation and, more frequently, as a result of a tumour-specific interstitial deletion on chromosome 1. The consequence of both these chromosomal alterations is overexpression of scl in the leukaemic cells. Despite the strong inference of a role in human T-ALL, scl has not yet been demonstrated to be causally involved in neoplastic transformation. We attempted to do this by generating transgenic mice in which scl expression was directed to the T cell lineage using the CD2 enhancer and the strong SR alpha viral promoter (CD2-scl mice). Three transgenic lines, all of which expressed the scl transgene at a high level, were bred and analysed. No alterations in T cell development were seen in the mice. Unexpectedly CD2-scl mice did not develop tumours, nor did the transgene enhance tumourigenesis by Moloney murine leukaemia virus. These findings throw into question the mechanism by which aberrant scl expression contributes to T cell leukaemogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7824274

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo.

Authors:  J H Caamaño; P Perez; S A Lira; R Bravo
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

2.  An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice.

Authors:  P D Aplan; C A Jones; D S Chervinsky; X Zhao; M Ellsworth; C Wu; E A McGuire; K W Gross
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

3.  CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease.

Authors:  K G Smith; A Strasser; D L Vaux
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

4.  Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha.

Authors:  M A Kelliher; D C Seldin; P Leder
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

5.  Helix-loop-helix proteins LYL1 and E2a form heterodimeric complexes with distinctive DNA-binding properties in hematolymphoid cells.

Authors:  A Miyamoto; X Cui; L Naumovski; M L Cleary
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

6.  The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells.

Authors:  G G Grütz; K Bucher; I Lavenir; T Larson; R Larson; T H Rabbitts
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

Review 7.  Stem Cell Leukemia: how a TALented actor can go awry on the hematopoietic stage.

Authors:  N C Correia; M-L Arcangeli; F Pflumio; J T Barata
Journal:  Leukemia       Date:  2016-06-13       Impact factor: 11.528

8.  Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo.

Authors:  M P Rubinstein; M L Salem; A N Kadima; C L Nguyen; W E Gillanders; M I Nishimura; D J Cole
Journal:  Cancer Gene Ther       Date:  2008-08-08       Impact factor: 5.987

9.  Cre-loxP-mediated recombination between the SIL and SCL genes leads to a block in T-cell development at the CD4- CD8- to CD4+ CD8+ transition.

Authors:  Yue Cheng; Zhenhua Zhang; Christopher Slape; Peter D Aplan
Journal:  Neoplasia       Date:  2007-04       Impact factor: 5.715

10.  Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.

Authors:  R C Larson; I Lavenir; T A Larson; R Baer; A J Warren; I Wadman; K Nottage; T H Rabbitts
Journal:  EMBO J       Date:  1996-03-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.